SequelSEC

VOLITIONRX LTD VNRX

In Vitro & In Vivo Diagnostic Substances · CIK 0000093314 · Fiscal year ends 1231

Revenue
$1.73M
Fiscal year ended 2025-12-31
Operating income
-$21.74M
Fiscal year ended 2025-12-31
Free cash flow
-$19.77M
Fiscal year ended 2025-12-31

VOLITIONRX LTD (VNRX) reported revenue of $1.73M and net income of -$23.36M for the fiscal year ended 2025-12-31. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from VOLITIONRX LTD’s SEC filings, each linked to the filing it came from. It is classified by the SEC under In Vitro & In Vivo Diagnostic Substances.

Income

VOLITIONRX LTD income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312014-12-31
Revenue$1.73M$1.23M$775.30K$306.39K$90.04K$13.43K$17.10K$14.78K
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$21.74M-$27.02M-$35.99M-$31.78M-$28.33M-$21.25M-$16.04M-$5.95M
Net income-$23.36M-$26.97M-$35.68M-$30.60M-$26.99M-$20.40M-$16.10M-$8.21M
Research & development$10.08M$14.41M$19.55M$15.33M$13.02M$14.53M$10.36M$4.04M
Weighted-average diluted sharesshares 106.83Mshares 86.53Mshares 71.23MUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPSUnavailable$-0.31$-0.50UnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$13.38M$13.85M$17.21M$16.75M$15.40M$6.73M$5.70MUnavailable
General & administrative$9.46M$8.49M$10.37M$10.18M$11.68M$5.65M$4.73M$299.05K
Selling & marketing$3.92M$5.36M$6.84M$6.58M$3.72M$1.07M$965.71KUnavailable

Balance

VOLITIONRX LTD balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312014-12-31
Cash & equivalents$1.12M$3.26M$20.73M$10.87M$20.58M$19.44M$16.97M$2.14M
Total assets$6.90M$9.40M$27.95M$18.30M$27.49M$26.15M$21.29M$3.43M
Current assets$2.06M$4.06M$21.85M$12.17M$21.98M$20.33M$17.56M$2.34M
Total liabilities$42.49M$35.51M$36.66M$21.42M$9.77M$9.86M$7.09M$3.06M
Current liabilities$12.23M$7.79M$8.94M$17.39M$6.52M$6.24M$3.86M$2.71M
Total equity incl. NCI-$35.59M-$26.11M-$8.71M-$3.13M$17.72M$16.29M$14.20M$368.18K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$317.81K$110.57K$242.62K$72.61K$12.51K$7.12K$0Unavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$5.82M$3.95M$3.62M$2.78M$2.27M$2.61M$2.20MUnavailable
Accounts payable$2.92M$2.77M$3.21M$3.04M$1.54M$1.54M$627.25KUnavailable

Cash flow

VOLITIONRX LTD cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312014-12-31
Operating cash flow-$19.68M-$25.89M-$18.06M-$15.28M-$20.85M-$16.46M-$12.74M-$4.14M
Capital expenditures$89.56K$277.50K$1.08M$1.57M$973.56K$1.94M$511.27K$302.99K
Investing cash flow-$89.56K-$573.85K-$1.08M-$1.57M-$973.56K-$1.65M-$511.27K-$302.99K
Financing cash flow$17.09M$8.66M$28.98M$6.94M$22.86M$20.62M$16.93M$5.74M
Net change in cash-$2.15M-$17.47M$9.86M-$9.71M$1.14M$2.48M$3.54M$1.25M
Stock-based compensation$1.74M$1.27M$2.29M$3.11M$2.45MUnavailable$1.46M$767.48K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailable$0$31.77K$0UnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$983.71K$1.11M$1.15M$936.08K$945.37K$716.18K$676.82K$142.13K

Derived

VOLITIONRX LTD derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312014-12-31
Free cash flow-$19.77M-$26.17M-$19.15M-$16.85M-$21.83M-$18.41M-$13.25M-$4.44M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-1258.5%-2190.9%-4641.8%-10372.4%-31469.0%-158176.2%-93840.2%Unavailable
FCF margin-1144.7%-2121.7%-2469.6%-5498.8%-24243.3%-137015.6%-77507.7%Unavailable
SBC / revenue100.7%102.8%295.3%1016.6%2721.6%UnavailableUnavailableUnavailable
Current ratio0.17x0.52x2.44x0.70x3.37x3.26x4.55x0.86x
Revenue YoY growth40.0%59.1%153.0%240.3%570.3%-21.4%UnavailableUnavailable
Net margin-1352.2%-2186.3%-4601.7%-9986.7%-29977.0%-151859.6%-94168.5%Unavailable
R&D / revenue583.6%1167.9%2521.8%5004.4%14463.7%108195.2%60618.0%Unavailable
CapEx / revenue5.2%22.5%139.8%512.5%1081.3%14449.9%2990.6%Unavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VNRX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.